Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MICHELLE: Rivaroxaban for Extended Thromboprophylaxis in COVID-19
NCT04662684Phase 3Completed
- Sponsor
- Science Valley Research Institute
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Science Valley Research Institute. Primary endpoint: Venous thromboembolism and VTE related-death at 35 days. Started Oct 2020; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04662684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662684.